FATE FY 2018 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+15.4% YoY

Gross Profit

-$51M-1081.9% margin

Operating Income

-$67M-1415.4% margin

Net Income

-$67M-1405.0% margin

EPS (Diluted)

$-1.19

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$41M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$213M

Total Liabilities

$53M

Stockholders' Equity

$160M

Cash & Equivalents

$191M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$4M	+15.4%
Gross Profit	-$51M	-$30M	-69.5%
Operating Income	-$67M	-$42M	-59.3%
Net Income	-$67M	-$43M	-55.1%